Study on hypothyroidism caused by treating metastatic clear cell renal cell carcinoma with small molecule VEGFR-TKI

DING Xiao-ying; WU Jian-qiu; ZHANG Xiao-mei; TANG Wei-Yan; FENG Ji-feng; KOU Ying-ying; TANG Yi-qun

doi:10.16462/j.cnki.zhjbkz.2016.06.014

Volume 20 Issue 6

Jun. 2016

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2016 > 20(6): 595-599

DING Xiao-ying, WU Jian-qiu, ZHANG Xiao-mei, TANG Wei-Yan, FENG Ji-feng, KOU Ying-ying, TANG Yi-qun. Study on hypothyroidism caused by treating metastatic clear cell renal cell carcinoma with small molecule VEGFR-TKI[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(6): 595-599. doi: 10.16462/j.cnki.zhjbkz.2016.06.014

Citation:

DING Xiao-ying, WU Jian-qiu, ZHANG Xiao-mei, TANG Wei-Yan, FENG Ji-feng, KOU Ying-ying, TANG Yi-qun. Study on hypothyroidism caused by treating metastatic clear cell renal cell carcinoma with small molecule VEGFR-TKI[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(6): 595-599. doi: 10.16462/j.cnki.zhjbkz.2016.06.014

Citation:

DING Xiao-ying, WU Jian-qiu, ZHANG Xiao-mei, TANG Wei-Yan, FENG Ji-feng, KOU Ying-ying, TANG Yi-qun. Study on hypothyroidism caused by treating metastatic clear cell renal cell carcinoma with small molecule VEGFR-TKI[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(6): 595-599. doi: 10.16462/j.cnki.zhjbkz.2016.06.014

PDF( 1142 KB)

Study on hypothyroidism caused by treating metastatic clear cell renal cell carcinoma with small molecule VEGFR-TKI

doi: 10.16462/j.cnki.zhjbkz.2016.06.014

1. Research Division of Pharmacology, China Pharmaceutical University, Nanjing 210009, China;
2. Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing 210009, China

Received Date: 2015-12-07
Rev Recd Date: 2016-03-29

Abstract

Abstract

Objective To investigate the incidence of hypothyroidism and efficacy of metastatic clear cell renal cell carcinoma treated with small molecule VEGFR-TKI. Methods A retrospective study was conducted to analyze the clinical data of 24 patients treated with TKI (Axitinib or Sorafenib) therapy(n=10) or cytokine therapy(n=14) from November 2009 to December 2010. The change trend of thyroid function index and prognosis between TKI group and control group were analyzed. Results TKI group with hypothyroidism was higher than control group(50.0% vs. 7.1%, χ²=5.714, P=0.017). The median time of hypothyroidism was 56.2 months, thyroid stimulating hormone (TSH) increased obviously, free thyroxine (FT4) decreased synchronously and free triiodothyronine (FT3) fall time was relatively lagging behind in TKI group. The median overall survival was 21(95% CI:0.001-54.200) months of TKI group versus 15(95% CI:4.000-26.000) months of control group (P=0.265). Conclusions The incidence of hypothyroidism of TKI group is significantly higher than the control group, the survival time is longer. The hypothyroidism is a common side effect of metastatic clear cell renal carcinoma patients receiving small molecule VEGFR-TKI. Long term monitoring thyroid function and timely intervention of hypothyroidism can improve the patient's treatment compliance and quality of life.
- Kidney neoplasms,
- Thyroid hypofunction,
- Epidemiologic methods

FullText(HTML)

References(19)

References

Jiang Z, Chu PG, Woda BA, et al. Combination of quantitative IMP3 and tumor stage:a new system to predict metastasis for patients with localized renal-cell-carcinomas [J]. Clin Cancer Res, 2008,14(17):5579-5584.

Shariat SF, Bolenz C, Karakiewicz PI. Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma:a randomised, double -blind phase III trial. Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigators [J]. Eur Urol, 2008,54(4):948-949.

Kakehi Y. Molecular targeted therapy for renal cell carcinoma [J]. Rinsho Ketsueki, 2008,49(8):622-625.

Cella D, Cappelleri JC, Bushmakin A, et al. Quality of life predicts progression free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa [J]. J Oncol Pract, 2009,5(2):66-70.

Culp SH, Wood CG. Words of wisdom. Re: Efficacy of everolimus in advanced renal cell carcinoma: a double -blind, randomized, placebo controlled phase III trial [J]. Eur Urol,2009,55(6):1484-1485.

Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma [J]. Drugs R D, 2011,11(2):113-126.

Wilhelm S, Chien DS. BAY 43-9006: preclinical data [J]. Curr Pharm Des, 2002,8(25):2255-2257.

Liu S, Kurzrock R. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms [J]. Cancer Treat Rev, 2014,40(7):883-891.

Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow [J]. Oncologist, 2011,16(Suppl 2):45-50.

Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal carcinoma [J]. J Clin Oncol, 2004,22(3):454-463.

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2014,25 Suppl 3:iii49-iii56.

Peréz-Solert R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents:is there a silver lining [J]. J Clin Oncol, 2005,23(22):5235-5246.

余国芳,林丽珠. 林丽珠辨治表皮生长因子受体抑制剂相关皮疹的经验探析 [J]. 世界科学技术˙中医药现代化, 2009,12(5):758-762.

Grünwald V, Soltau J, Ivanyi P,et al. Molecular targeted therapies for solid tumors: management of side effects [J]. Onkologie. 2009,32(3):129-138.

Mukohara T, Nakajima H, Mukai H, et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone and biomarkers: a phase I study in Japanese patients [J]. Cancer Sci, 2010,101(4):963-968.

Viktor Grünwald, Axel S Merseburger. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment [J]. Onco Targets Ther,2012,5:111-117.

Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma:An expanded-access trial [J]. Lancet Oncol, 2009,10(8):757-763.

Clemons J, Gao D, Naam M, et al. Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib [J]. Clin Genitourin Cancer, 2012,10(4): 225-231.

Ueda T, Uemura H, Tomita Y, et al. Efficacy and safety of axitinib versus sorafenib in advanced renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized phase 3 AXIS trial [J]. Jpn J Clin oncol, 2013,43(6):616-628.

Relative Articles

Supplements(0)

Cited By

Proportional views